India is reviewing its months-long tariff-related reduction for the pharmaceutical trade amid the evolving scenario in West Asia and is more likely to lengthen the exemption past June 30, a senior official from the Middle’s commerce ministry stated right here on Tuesday.
“We’re reviewing it every day… there’s a chance of an extension (of the exemption),” Deputy Commissioner Ravi Teja instructed the media, pointing to the obligation exemption granted by the federal government for important petrochemical merchandise.
The federal government had introduced measures to make sure the continued availability of important petrochemical feedstocks for home trade, cut back value pressures on downstream sectors and defend safety of provide throughout the nation. The scheme was aimed toward supporting numerous sectors depending on petrochemical uncooked supplies and intermediate merchandise, together with plastics, packaging, textiles, prescribed drugs, chemical substances, auto elements and different manufacturing industries.
Tariff reduction has been launched for sure chemical substances and solvents utilized in pharmaceutical manufacturing. It additional stated that measures have been initiated to offset rising freight and insurance coverage prices, including that the affect of the West Asian disaster on pharmaceutical provides and exports can be restricted.
The federal government can be specializing in market diversification to make sure continued development in pharmaceutical exports, with the worth of pharmaceutical exports reaching simply over $31 billion in FY2026.
India is the third largest producer of prescribed drugs, supplying roughly 20% of the world’s demand for generic medicine, with over 60% of exports going to extremely regulated markets.
Ravi Teja stated the following part of development can be outlined by India’s transfer from quantity to worth. Generic medicine will stay the cornerstone. The long run may also be formed by biosimilars, biologics, gene therapies, specialty medicines, vaccines, advanced generic medicines, contract manufacturing capabilities, and medical units.
India is pursuing a goal of $50 billion in pharmaceutical exports by 2030 and goals to attain the identical set to strengthen high quality methods and construct resilience in lively pharmaceutical elements and key beginning supplies. Along with market diversification, emphasis has been positioned on regulatory cooperation, particularly acceptance of the Indian Pharmacopoeia by extra nations, with over 20 nations now accepting this normal.
